Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers

PURPOSE: Novel biomarkers to better predict outcome and select the best therapeutic strategy for the individual patient are necessary for pancreatic ductal adenocarcinoma (PDAC). METHODS: Using a panel assay, multiple biomarkers (IFN-γ, IL-10, IL-6, IL-8, TNF-α, CEA, CA 19–9, CYFRA 21–1, HE4, PD-1 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorman, Klara, Gerckens, Miriam, Kruger, Stephan, Krueger, Kimberly, Mayer, Zsuzsanna, Rupp, Alexander, Zhang, Danmei, Weiss, Lena, Westphalen, C. Benedikt, Haas, Michael, Guenther, Michael, Ormanns, Steffen, Klawonn, Frank, Werner, Jens, von Bergwelt-Baildon, Michael, Heinemann, Volker, Boeck, Stefan, Holdenrieder, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130000/
https://www.ncbi.nlm.nih.gov/pubmed/35737090
http://dx.doi.org/10.1007/s00432-022-04112-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130000/
https://www.ncbi.nlm.nih.gov/pubmed/35737090
http://dx.doi.org/10.1007/s00432-022-04112-z

Ejemplares similares